Pathophysiological aspects of human neurodegenerative diseases

Wiener Klinische Wochenschrift

Volumn 109, Issue 16, 1997, Pages 623-635

  Hörtnagl, Heide ^a,b   Hellweg, Rainer ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Cytokines; Disease genes; Huntington's disease; Neurotrophic factors; Oxidative stress; Parkinson's disease; Pathogenesis

Indexed keywords

NEUROTRANSMITTER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CYTOPATHOGENIC EFFECT; GENETIC SUSCEPTIBILITY; HUMAN; HUNTINGTON CHOREA; NEUROTOXICITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW;

AMYLOID BETA-PROTEIN; APOPTOSIS; BRAIN; CHROMOSOME MAPPING; CYTOKINES; EXCITATORY AMINO ACIDS; HUMANS; LINKAGE (GENETICS); NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 0030767741     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi, RE, et al (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234-238
2. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983
3. Martin JB (1993) Molecular genetics of neurological diseases. Science 262: 674-676
4. Claes S, Van Zand K, Legius E, Dom R, Malfroid M, Baro F, et al (1995) Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 52: 749-753
5. Burke JR, Enghild JJ, Martin ME, Jou Y-S, Myers RM, Roses AD, et al (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Medicine 2: 347-350
6. Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91: 5355-5358
7. Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, et al (1996) Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci USA 93: 5037-5042
8. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706
9. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al (1995) Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 375: 754-760
10. Levy-Lahad E, Wijsman EM, Nemens E, Andersen L, Goddard KAB, Weber JL, et al (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269: 970-973
11. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977
12. Roagev EI, Sherrington R, Rogaeva E, Levesque G, Ikeda M, Liang Y, et al (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778
13. Tsuda T, Chi H, Liang Y, Rogaeva EA, Sherrington R, Levesque G, et al (1995) Failure to detect missense mutations in the S182 gene in a series of late-onset Alzheimer's disease cases. Neurosci Lett 201: 188-190
14. Anwar R, Moynihan TP, Ardley H, Brindle N, Coletta PL, Cairns N, et al (1996) Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: identification and characterization of unusual splice variants. J Neurochem 66: 1774-1777
15. Saunders AM, Strittmatter WJ, Schmcchel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, et al (1993) Association of apolipoprotein E allele ε4 with late onset familiar and sporadic Alzheimer's disease. Neurology 43: 1467-1472
16. Houlden H, Crook R, Duff K, Collinge J, Roques P, Rossor M, Hardy J (1993) Confirmation that the apolipoprotein E4 allele is associated with late onset, familial Alzheimer's disease. Neurodegeneration 2: 283-286
17. Strittmatter WJ, Roses AD (1995) Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci USA 92: 4725-4727
18. Kuusisto J, Koivisto K, Kervinen K, Mykkänen L, Helkala E-L, Vanhanen M, et al (1994) Association of apolipo-protein E phenotypes with late onset Alzheimer's disease: population based study. Br Med J 309: 636-638
19. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al (1995) Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 333: 1242-1247
20. Poirier J (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 17: 525-530
21. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S, et al (1995) A severe loss of cho- line actetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele. Neurosci Lett 187: 79-82
22. Helkala E-L, Koivisto K, Hänninen T, Vanhanen M, Kervinen K, Kuusisto J, et al (1996) Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett 204: 177-180
23. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr PC, et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimers disease. Nature Genet 7: 180-184
24. Lannfelt L, Lilius L, Nastase M, Viitanen M, Fratiglioni L, Eggertsen G, et al (1994) Lack of association between apolipoprotein E allele ε4 and sporadic Alzheimer's disease. Neurosci Lett 169: 175-178
25. Farrer LA, Cupples LA, van Duijn CM, Kurz A, Zimmer R, Muller U, et al (1995) Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Ann Neurol 38: 797-808
26. Hyman BT, Gomez-Isla T, Briggs M, Chung H, Nichols S, Kohout F, Wallace R (1996) Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 40: 55-66
27. Myers RH, Schaefer EJ, Wilson PWF, Dagostino R, Ordovas JM, Espino A, et al (1996) Apolipoprotein E ε4 association with dementia in a population-based study: the Framingham study. Neurology 46: 673-677
28. Frisoni GB, Calabresi L, Geroldi C, Bianchetti A, D'Acquarica AL, Govoni S, et al (1994) Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia 5: 240-242
29. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM (1995) Apolipoprotein E type ε4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 202: 101-104
30. Helisalmi P, Linnaranta K, Lehtovirta M, Mannermaa A, Heinonen O, Ryynänen M, et al (1996) Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Neurosci Lett 205: 61-64
31. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell Jr PC, Rimmler JB, et al (1995) Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risk of death and Alzheimer's disease. Neurology 45: 1323-1328
32. Dalforno G, Rasmusson X, Brandt J, Carson KA, Brookmeyer R, Troncoso J, Kawas CH (1996) Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 53: 345-350
33. van Duijn CM, de Knijff P, Wehnert A, De Voecht J, Bronzova JB, Havekes LM, et al (1995) The apolipoprotein E ε2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 37: 605-610
34. Marder K, Maestre G, Cote L, Mejia H, Alfaro B, Halim A, et al (1994) The apolipoprotein ε4 allele in Parkinson's disease with and without dementia. Neurology 44: 1330-1331
35. Koller WC, Glatt SL, Hubble JP, Paolo A, Troster AI, Handler MS, et al (1995) Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 37: 242-245
36. Mui S, Rebeck GW, Mckennayasek D, Hyman BT, Brown RH (1995) Apolipoprotein E ε4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 38: 460-463
37. Salvatore M, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, Sorbi S, et al (1995) Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neurosci Lett 199: 95-98
38. Mann DMA, Pickering-Brown SM, Siddons MA, Iwatsubo T, Ihara Y, Asamiodaka A, Suzuki N (1995) The extent of amyloid deposition in brain of patients with Down's syndrome does not depend upon the apolipoprotein E genotype. Neurosci Lett 196: 105-108
39. Seshadri S, Drachman DA, Lippa CF (1995) Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease. Arch Neurol 52: 1074-1079
40. Roses AD (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease. Ann Neurol 38: 6-14
41. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease Proc Natl Acad Sci USA 92: 12260-12264
42. Thome J, Baumer A, Kornhuber J, Rosler R, Riederer P (1995) α1-antichymotrypsin bi-allele polymorphism, apolipoprotein E tri-allele polymorphism and genetic risk of Alzheimer's syndrome. J Neural Transm [P-D Sect] 10: 207-212
43. Siddique T, Figlewicz DA, Pericak-Vance MA, Haines JL, Rouleau G, Jeffers AJ, et al (1991) Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 324: 1381-1384
44. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62
45. Deng H-X, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung W-Y. et al (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261: 1047-1051
46. Rouleau GA, Clark AW, Rooke K, Pramatarova A, Krizus A, Suchowersky O, et al (1996) SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol 39: 128-131
47. Carrero-Valenzuela R, Lindblad K, Payami H, Johnson W, Schalling M, Stenroos ES, et al (1995) No evidence for association of familial Parkinson's disease with CAG repeat expansion. Neurology 45: 1760-1763
48. Parboosingh JS, Rousseau M, Rogan F, Amit Z, Chertkow H, Johnson WG, et al (1995) Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 52: 1160-1163
49. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, et al (1992) Debrisoqume hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339: 1375-1377
50. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 1197-1199
51. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366
52. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379-387
53. Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593-602
54. Zorumski CF, Olney JW (1993) Excitotoxic neuronal damage and neuropsychiatric disorders. Pharmac Ther 59: 142-162
55. Dodd PR, Scott HL, Westphalen RI (1994) Excititoxic mechanisms in the pathogenesis of dementia. Neurochem Int 25: 203-219
56. Rothstein JD, Martin LJ, Kunci RW (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464-1468
57. Eisen A, Stewart H, Schulzer M, Cameron D (1994) Anti-glutamate therapy in amyotrophic lateral sclerosis a trial using lamotriginc. Can J Neurol Sci 20: 297-301
58. Bensimon G, Lacomblez I, Meininger V, the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585-591
59. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, et al (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 50: 790-802
60. Simonian NA, Coyle JT (1996) Oxidative stress in neurodegenerative diseases. Ann Rev Pharmacol Toxicol 36: 83-106
61. Olanow CW (1993) A radical hypothesis for neurodegeneration. Trends Neurosci 16: 439-444
62. Warner HR (1994) Superoxide dismutase, aging and degenerative disease. Free Radical Biol Med 17: 249-258
63. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 63: 793-807
64. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR (1994) The iron-binding protein lactotransferrin is present in pathological lesions in a variety of neurode-generative disorders: a comparative immunohistochemical analysis. Brain Res 650: 20-31
65. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoferritins in selected regions of aged, Parkinsonian, and Alzheimer's diseased brains. J Neurochem 65: 717-724
66. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695
67. Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796-798
68. Benzi G, Pastoris O, Marzatico F, Villa RF (1989) Cerebral enzyme antioxidant system. Influence of aging and phosphatidylcholine. J Cereb Blood Flow Metab 9: 373-380
69. Harman D (1993) Free radical theory of aging: a hypothesis on pathogenesis of senile dementia of the Alzheimer's type. Age 16: 23-30
70. Bowling AC, Beal MF (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56: 1151-1171
71. De Erausquin GA, Costa E, Hanbauer I (1994) Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol Rev 46: 467-482
72. Soong NW, Hinton DR, Cortopassi G, Arnheim N (1992) Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nature Genet 2: 318-323
73. Graham DG, Tiffany SM, Bell Jr WR, Gulknecht WF (1987) Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine. and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644-653
74. Faucheux BA, Nillesse N, Damier P, Spik G, Mouattprigent A, Pierce A, et al (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Natl Acad Sci USA 92: 9603-9607
75. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355
76. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione related enzymes in brain in Parkinson's disease. Ann Neurol 36: 356-361
77. Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
78. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased lipid peroxidation in vitro. J Neurochem 55: 342-345
79. Zhou Y, Richardson JS, Mombourquette MJ, Weil JA (1995) Free radical formation in autopsy samples of Alzheimer and control cortex. Neurosci Lett 195: 89-92
80. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, et al (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216-1223
81. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, Demaggio AJ, et al (1995) Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65: 710-716
82. Friedlich AL, Butcher LL (1994) Involvement of free oxygen radicals in beta-amyloidosis: an hypothesis. Neurobiol Aging 15: 443-455
83. Benzi G, Moretti A (1995) Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 16: 661-674
84. Parker Jr WD, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40: 1302-1303
85. Lin F-H, Lin R, Wisniewski HM, Hwang Y-W, Grundke-Iqbal F, Healy-Louie G, Iqbal K (1992) Detection of point mutations in codon 331 of mitochondrial dehydrogenase subunit 2 in Alzheimer's brains. Biochem Biophys Res Comm 182: 238-246
86. Mecocci P, Macgarvay U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease Ann Neurol 36: 747-751
87. Darleyusmar V, Wiseman H, Hall Swell B (1995) Nitric oxide and oxygen radicals: a question of balance. FEES Lett 369: 131-135
88. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al (1989) Brain interleukin-1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 86: 7611-7622
89. Rothwell NJ, Relton JK (1993) Involvement of cytokines in acute neurodegeneration in the CNS. Neurosci Biobehav Rev 17: 217-227
90. Rothwell NJ, Strijbos PJLM (1995) Cytokines in neurodegeneration and repair. Int J Develop Neurosci 13: 179-185
91. Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Larlow B, Wolf-Klein G (1991) Elevated tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 129: 318-320
92. 2-macroglobuline indicate an acute phase state in Alzheimer's disease cortices. FEBS Lett 285: 111-114
93. Hu̇ll M, Strauss S, Berger M, Volk B, Bauer J (1996) The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res 78: 37-41
94. 2-macroglobuline and C-reactive protein. Brain Res 629: 245-252
95. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's disease and de novo Parkinson's disease patients. Neurosci Lett 202: 17-20
96. Griffin WST, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 54: 276-281
97. Holden RJ, Mooney PA (1995) Interleukin-1β: a common cause of Alzheimer's disease and diabetes mellitus. Med Hypothesis 45: 559-571
98. McGeer PL, McGeer EG (1995) The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21: 195-218
99. Aisen PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 151: 1105-1113
100. Rogers J (1995) Inflammation as a pathogenetic mechanism in Alzheimer's disease. Arzneimittelforsch/Drug Res 45: 439-442
101. McGeer PL, McGeer EG, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer's disease. Lancet 335: 1037
102. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44: 227-232
103. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A (1995) Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45: 1441-1445
104. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611
105. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994) Neurotrophic factors: from molecule to man. Trends Neurosci 17: 182-190
106. Scott SA, Crutcher KA (1994) Nerve growth factor and Alzheimer's disease. Rev Neurosci 5: 179-211
107. Mattson MP, Scheff SW (1994) Endogenous protection factors and traumatic brain injury: mechanisms of action and implications for therapy. J Neurotrauma 11: 3-33
108. Alberts MJ, Pericak-Vance MA, Royal V, Bebout J, Gaskell P, Thomas J, et al (1991) Genetic linkage analysis of nerve growth factor (beta) in familial Alzheimer's disease. Ann Neurol 30: 216-219
109. Goedert UE, Fine A, Hunt SP, Ullrich A (1986) Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Mol Brain Res 1: 85-92
110. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702
111. Jetté N, Cole MS, Fahnestock M (1994) NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol Brain Res 25: 242-250
112. Fahnestock M, Scott SA, Jette N, Weingartner JA, Crutcher KA (1996) Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Mol Brain Res 42: 175-178
113. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA (1995) Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15: 6213-6221
114. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 2925-2928
115. Mufson EJ, Conner JM, Kordower JH (1995) Nerve growth in Alzheimer's disease: defective retrograde transport to nucleus basalis. NeuroReport 6: 1063-1066
116. Strada O, Hirsch EC, Javoy-Agid F, Lehéricy S, Ruberg M, Hauw J-J, Agid Y (1992) Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain J Neurosci 12: 4766-4774
117. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19: 514-520
118. Connor B, Young D, Lawlor P, Gai W, Waldvogel H, Faull RLM, Dragunow M (1996) Trk receptor alterations in Alzheimer's disease. Mol Brain Res 42: 1-17
119. Anand P, Parrett A, Martin J, Zeman S, Foley P, Swash M, et al (1995) Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease. Nature Med 1: 168-172
120. trkB mRNA in amyotrophic lateral sclerosis. Brain Res 621: 111-115
121. Adem A, Ekblom J, Gillberg PG (1994) Growth factor receptors in amyotrophic lateral sclerosis. Mol Neurobiol 9: 225-231
122. Villares J, Strada O, Faucheux B, Javoy-Agid F, Agid Y, Hirsch EC (1994) Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease. Neurosci Lett 182: 59-62
123. Hörtnagl H, Hellweg R (1997) New insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies? Brain Res Bull (in press)
124. Hardy J (1992) An "anatomical cascade hypothesis" for Alzheimer's disease. Trends Neurosci 15: 200-201
125. Cai X-D, Golde TE, Younkin SG (1993) Release of excess amyloid β-protein from a mutant amyloid β-protein precursor. Science 259: 514-516
126. 717) mutants. Science 264: 1336-1340
127. Sisodia SS, Price DL (1995) Role of β-amyloid protein in Alzheimer's disease. FASEB J 9: 366-370
128. Selkoe DJ (1996) Amyloid β-protein and the genetics of Alzheimer's disease, J Biol Chem 271: 18295-18298
129. Ii K (1995) The role of β-amyloid in the development of Alzheimer's disease. Drugs & Aging 7: 97-109
130. Koh J, Yang LL, Cotman CW (1990) β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315-320
131. . Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) β-Amyloid peptides destabilize cal- cium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389
132. Hoyer S (1994) Neurodegeneration. Alzheimer's disease, and beta-amyloid loxicity. Life Sci 55: 1977-1983
133. Saitoh T, Brugge K (1994) Is amyloid causally involved in pathophysiology of Alzheimer's disease? Neurobiol Aging 15: 461-462
134. Mann DMA, Brown AMT, Prinja D, Jones D, Davies CA (1990) A morphometric analysis of senile plaques in the brains of nondemented persons of different ages using silver, immunocytochemical and lectin histochemical staining techniques. Neuropathol Appl Neurobiol 16: 17-25
135. Selkoe DJ (1994) Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 53: 438-447
136. Robakis NK, Pappolla MA (1994) Oxygen-free radicals and amyloidosis in Alzheimer's disease: is there a connection. Neurobiol Aging 15: 457-459
137. Citron M, Diehl TS, Capell A, Haass C, Teplow DB, Selkoe DJ (1996) Inhibition of amyloid β-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron 17: 171-179
138. Nitsch RM, Growdon JH (1994) Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem Pharmacol 47: 1275-1284
139. Disterhoft JF, Thompson LT, Weiss C, Moyer JR, Van der Zee E, Carillo M, et al (1995) The calcium hypothesis for Alzheimer's disease: insights from animal and human studies. Neurosci Res Comm 17: 121-131
140. Biessels G, Gispen WH (1996) The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Life Sci 59: 379-387
141. Mattson MP (1995) Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid β-peptide? Neurobiol Aging 16: 679-682
142. 2T channels provides a mechanism for neuronal death in Alzheimer's disease. Ann NY Acad Sci 747: 256-266
143. Meier-Ruge W, Bertoni Freddari C, Iwangoff P (1994) Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 40: 246-252
144. Henneberg N, Hoyer S (1995) Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of lare-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatrics 21: 63-74
145. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, et al (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17: 123-130
146. Smith MA, Taneda S, Richey PL, Miyata S, Yan S-D, Stern D, et al (1994) Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 91: 5710-5714
147. De la Torre (1994) Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Biobehav Rev 18: 397-401
148. Thompson CG (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462
149. Cotman CW, Anderson AJ (1995) A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 10: 19-45
150. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35-41
151. Dragunow M, Faull RLM, Lawlor P, Beilharz EJ, Single- ton K, Walker EB, Mee E (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobe. Neuroreport 6: 1053-1057
152. Satou T, Cummings BJ, Cotman CW (1995) Immuno-reactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res 697: 35-43
153. Alexianu ME, Mohamed AH, Smith RG, Colom LV, Appel SH (1994) Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J Neurochem 63: 2365-2368
154. Troost D, Aten J, Morsink F, de Jong JMBV (1995) Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Neuropath Appl Neurobiol 21: 498-504
155. Portera-Cailliau C, Herdreen JC, Price DL, Koliatsos VE (1995) Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. J Neurosci 15: 3775-3787
156. Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A (1994) Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 170: 136-140
157. Walkinshaw G, Waters CM (1994) Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 63: 975-987
158. Katzman R (1993) Education and the prevalence of dementia and Alzheimer's disease. Neurology 43: 13-20
159. Amaducci L, Lippi A (1994) Risk factors for dementia. In: Burns A, Levy R (eds) Dementia. Chapman & Hall, London, pp 129-141
160. Toran-Allerand CD, Miranda RC, Bentham WD, et al (1992) Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 89: 4668-4672
161. Gibbs RB, Wu D-H, Hersh L, Pfaff DW (1994) Effects of estrogen replacement on relative levels of choline acetyl-transferase, trkA, and nerve growth factor messenger RNAs in the basal forebrain and hippocampal formation of adult rats. Exp Neurol 129: 70-80
162. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE (1994) Estrogen regulates metabolism of Alzheimer's amyloid beta precursor protein. J Biol Chem 269: 13065-13068
163. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG (1994) Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51: 896-900
164. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R (1996) Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 348: 429-432
165. Dugan LL, Choi DW (1994) Excitotoxicity, free radicals, and cell membrane changes. Ann Neurol 35: S17-S21
166. Choi BH (1995) Oxidative stress and Alzheimer's disease. Neurobiol Aging 16: 675-678
167. Davis JN, Hunnicutt EJ, Chisholm JC (1995) A mitochondrial bottleneck hypothesis of Alzheimer's disease. Mol Med Today 1: 240-247